Skip to main content

Table 4 Stage and treatment of patients with adenocarcinoma (n = 295)

From: Intravenous sedation during esophagogastroduodenoscopy is associated with a reduced risk of missed gastric cancer

 

Non-MGC

MGC

p

Stage (n = 263*), n (%)

  

0.684

 IA (early)

33 (13.3)

3 (21.4)

 

 IB-III (potentially resectable)

121 (48.6)

6 (42.9)

 

 IV (advanced)

95 (38.1)

5 (35.7)

 

Treatment (n = 283**), n (%)

  

0.225

 Endoscopic resection/Surgery

70 (26.3)

6 (35.3)

 

 Surgery + chemotherapy

84 (31.6)

2 (11.8)

 

 Chemotherapy/palliative

112 (42.1)

9 (52.9)

 
  1. MGC = missed Gastric Cancer; SD = standard deviation
  2. *32 patients with unavailable information
  3. **12 patients with unavailable information